I have covered AcelRx Pharmaceuticals (ACRX) before, so investors should view this as an update to my previous articles.
On March 16, 2020 ACRX published its fiscal year 2019 financial statements. The financials per se did not contain much new key information after the company had pre-released key data on formulary approvals/REMS certifications, liquidity and revenue on January 13, 2020 (discussed in more detail below).
Thus, the main item of interest on March 16 was the announcement that ACRX intends to acquire Tetraphase Pharmaceuticals (TTPH) in an all-stock deal,